

**Sun Pharma Laboratories Limited**

Regd. Office : Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
www.spil.co  
CIN : U25200MH1997PLC240268



May 24, 2018

**General Manager**  
**BSE Limited,**  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001  
Scrip Codes: 953164  
ISIN Nos: INE915T08024

Dear Sir,

**Sub: Outcome of the Board Meeting**

The Board of Directors of the Company at their meeting held today i.e. May 24, 2018 duly approved and took on record the Audited Financial Results for the half year and year ended March 31, 2018

Pursuant to Regulation 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") we are enclosing herewith the following:

- a) Standalone Audited Financial Results for the half year and year ended March 31, 2018 along with details required under Regulation 52(4) of SEBI Listing Regulations.
- b) Auditor's Report on Standalone Financial Results.
- c) Declaration regarding Standalone Audit Report with unmodified opinion.
- d) Certificate from the Debenture Trustee as per Regulation 52(5) of SEBI Listing Regulations.

This is for your information and record.

Thanking you,

Yours faithfully,  
**For Sun Pharma Laboratories Limited**

**Rachana Kokal**  
**Company Secretary & Compliance Officer**

**Encl: As above.**

**Sun Pharma Laboratories Limited**

Registered Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 Tel.: +91 22 4324 4324.  
CIN: U25200MH1997PLC240268

**Statement of Standalone Audited Financial Results for the Half Year and Year ended March 31, 2018**

(₹ in Lakhs)

| Particulars  | Half Year ended           |                           | Year ended     |                |
|--|---------------------------|---------------------------|----------------|----------------|
|  | 31.03.2018                | 31.03.2017                | 31.03.2018     | 31.03.2017     |
|  | Audited<br>(Refer Note 9) | Audited<br>(Refer Note 9) | Audited        | Audited        |
| <b>I Revenue from Operations</b>   |                           |                           |                |                |
| <b>a. Sale of Products</b>   | 251,945                   | 260,038                   | 510,991        | 528,739        |
| <b>b. Other Operating Revenues</b>   | 9,548                     | 2,068                     | 10,136         | 3,550          |
| <b>Total Revenue from Operations (I)</b>   | <b>261,493</b>            | <b>262,106</b>            | <b>521,127</b> | <b>532,289</b> |
| <b>II Other Income</b>   | 10,501                    | 12,632                    | 25,852         | 22,865         |
| <b>III Total Income (I+II)</b>   | <b>271,994</b>            | <b>274,738</b>            | <b>546,979</b> | <b>555,154</b> |
| <b>IV Expenses</b>   |                           |                           |                |                |
| Cost of materials consumed   | 31,979                    | 44,309                    | 78,061         | 93,193         |
| Purchases of stock-in-trade  | 29,147                    | 12,518                    | 38,552         | 35,112         |
| Changes in inventories of finished goods, stock-in-trade and work-in-progress                                      | (573)                     | 5,399                     | 6,151          | 7,823          |
| Employee benefits expense  | 29,465                    | 23,202                    | 57,436         | 48,555         |
| Finance costs  | 7,016                     | 8,321                     | 13,320         | 14,763         |
| Depreciation and amortisation expense  | 80,404                    | 80,061                    | 161,121        | 159,698        |
| Other expenses   | 33,835                    | 49,950                    | 76,514         | 99,100         |
| <b>Total Expenses (IV)</b>   | <b>211,273</b>            | <b>223,760</b>            | <b>431,155</b> | <b>458,244</b> |
| <b>V Profit before Tax (III-IV)</b>  | <b>60,721</b>             | <b>50,978</b>             | <b>115,824</b> | <b>96,910</b>  |
| <b>VI Tax Expense</b>  | 15,473                    | 10,208                    | 28,202         | 21,067         |
| <b>VII Profit for the period (V-VI)</b>  | <b>45,248</b>             | <b>40,770</b>             | <b>87,622</b>  | <b>75,843</b>  |
| <b>VIII Other Comprehensive Income (OCI)</b>   |                           |                           |                |                |
| Items that will not be reclassified to profit or loss net of tax   | 2,196                     | (1,025)                   | 1,296          | (1,636)        |
| Tax on above   | (765)                     | 355                       | (453)          | 566            |
| Items that will be reclassified to profit or loss net of tax   | (115)                     | -                         | (95)           | -              |
| Tax on above   | 38                        | -                         | 33             | -              |
| <b>Total Other Comprehensive Income (VIII)</b>   | <b>1,354</b>              | <b>(670)</b>              | <b>781</b>     | <b>(1,070)</b> |
| <b>IX Total Comprehensive Income for the period (VII+VIII)</b>   | <b>46,602</b>             | <b>40,100</b>             | <b>88,403</b>  | <b>74,773</b>  |
| <b>X Paid-up Equity Share Capital - Face Value ₹ 10 each</b>   | 5                         | 5                         | 5              | 5              |
| <b>XI Paid-up Debt Capital (Non-convertible Debentures)</b>  | 50,000                    | 100,000                   | 50,000         | 100,000        |
| <b>XII Reserve excluding revaluation reserve (including Debenture Redemption Reserve) as at Balance Sheet date</b> |                           |                           | 1,966,882      | 1,974,161      |
| <b>XIII Debenture Redemption Reserve</b>   | 12,500                    | 20,834                    | 12,500         | 20,834         |
| <b>XIV Earnings Per Equity Share of ₹ 10 each (not annualised)</b>   |                           |                           |                |                |
| ₹ (Basic and Diluted)  | <b>90,496</b>             | <b>80,578</b>             | <b>173,318</b> | <b>150,724</b> |
| <b>XV Debt Equity Ratio</b>  |                           |                           | 1.7            | 1.1            |
| <b>XVI Debt Service Coverage Ratio</b>   | 1.2                       | 7.1                       | 2.0            | 7.6            |
| <b>XVII Interest Service Coverage Ratio</b>  | 9.7                       | 7.1                       | 9.7            | 7.6            |

See accompanying notes to the standalone audited financial results



**Sun Pharma Laboratories Limited**

Registered Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E),  
Mumbai - 400063 Tel.: +91 22 4324 4324.

CIN: U25200MH1997PLC240268

**Notes :**

**1 Statement of Standalone Assets and Liabilities**

(₹ in Lakhs)

| Particulars                               | As at<br>31.03.2018<br>Audited | As at<br>31.03.2017<br>Audited |
|---|--------------------------------|--------------------------------|
| <b>ASSETS</b>                             |                                |                                |
| <b>(1) Non-current assets</b>             |                                |                                |
| (a) Property, plant and equipment         | 112,981                        | 96,970                         |
| (b) Capital work-in-progress              | 21,153                         | 22,008                         |
| (c) Intangible assets                     | 917,912                        | 1,070,335                      |
| (d) Investments in subsidiaries           | 150                            | 150                            |
| (e) Investments in associates             | 830,100                        | 706,256                        |
| (f) Financial assets                      |                                |                                |
| (i) Investments                           | 6,453                          | 6,548                          |
| (ii) Loans                                | 25,409                         | 32                             |
| (iii) Other financial assets              | 1,583                          | 1,451                          |
| (g) Income tax assets (Net)               | 43,203                         | 45,081                         |
| (h) Other non-current assets              | 12,186                         | 9,292                          |
| <b>Total non-current assets</b>           | <b>1,971,130</b>               | <b>1,958,123</b>               |
| <b>(2) Current assets</b>                 |                                |                                |
| (a) Inventories                           | 45,963                         | 49,930                         |
| (b) Financial assets                      |                                |                                |
| (i) Investments                           | 47,565                         | 16,755                         |
| (ii) Trade receivables                    | 90,397                         | 62,369                         |
| (iii) Cash and cash equivalents           | 82                             | 96                             |
| (iv) Bank balances other than (iii) above | 205                            | 262                            |
| (v) Loans                                 | 75,714                         | 96,144                         |
| (vi) Other financial assets               | 21,000                         | 323                            |
| (c) Other current assets                  | 25,287                         | 15,989                         |
| <b>Total current assets</b>               | <b>306,213</b>                 | <b>241,868</b>                 |
| <b>TOTAL ASSETS</b>                       | <b>2,277,343</b>               | <b>2,199,991</b>               |
| <b>EQUITY AND LIABILITIES</b>             |                                |                                |
| <b>Equity</b>                             |                                |                                |
| (a) Equity share capital                  | 5                              | 5                              |
| (b) Other equity                          | 1,968,232                      | 1,975,573                      |
| <b>Total equity</b>                       | <b>1,968,237</b>               | <b>1,975,578</b>               |
| <b>Liabilities</b>                        |                                |                                |
| <b>(1) Non-current liabilities</b>        |                                |                                |
| (a) Financial liabilities                 |                                |                                |
| (i) Borrowings                            | -                              | 53,588                         |
| (b) Provisions                            | 3,925                          | 5,567                          |
| (c) Deferred tax liabilities (Net)        | 5,593                          | 2,071                          |
| <b>Total non-current liabilities</b>      | <b>9,518</b>                   | <b>61,226</b>                  |
| <b>(2) Current liabilities</b>            |                                |                                |
| (a) Financial liabilities                 |                                |                                |
| (i) Borrowings                            | 138,183                        | 29,824                         |
| (ii) Trade payables                       | 69,168                         | 48,588                         |
| (iii) Other financial liabilities         | 57,529                         | 56,872                         |
| (b) Other current liabilities             | 13,602                         | 4,413                          |
| (c) Provisions                            | 21,106                         | 23,490                         |
| <b>Total current liabilities</b>          | <b>299,588</b>                 | <b>163,187</b>                 |
| <b>Total liabilities</b>                  | <b>309,106</b>                 | <b>224,413</b>                 |
| <b>TOTAL EQUITY AND LIABILITIES</b>       | <b>2,277,343</b>               | <b>2,199,991</b>               |

**SIGNED FOR IDENTIFICATION**  
BY   
**S R B C & CO LLP**  
**MUMBAI**



**Notes :**

- 2 The above standalone audited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 24, 2018.
- 3 The Board has recommended payment of dividend of ₹ 10 per preference share of ₹ 100 each and ₹ 95,000 per equity share of ₹10 each for the year ended March 31, 2018 subject to approval of the members at ensuing Annual General Meeting.
- 4 The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS and other accounting principles generally accepted in India as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder.
- 5 The Company has issued rated unsecured listed redeemable non-convertible debentures (NCDs) during December 2015, which have been rated "[ICRA]AAA(stable)" by ICRA Limited. These standalone audited financial results have been prepared pursuant to Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Certain required ratios and additional disclosures have been presented in these standalone audited financial results.
  - (i) Debt Equity Ratio = (Long-term Borrowings + Short-term Borrowings + current maturities of Long-term Borrowings) / (Equity Share Capital + Other Equity excluding Capital Reserve)
  - (ii) Debt Service Coverage Ratio = Earnings before Interest Expense (Finance Costs) and Tax / (Interest Expense (Finance Costs) + Principal Repayment made during the period for long-term borrowings)
  - (iii) Interest Service Coverage Ratio = Earnings before Interest Expense (Finance Costs) and Tax / Interest Expense (Finance Costs)
  - (iv) Asset cover available as on March 31, 2018 is 6.5 times. Asset Cover = (Total Assets - Intangible Assets - Current Liabilities excluding Short-term Borrowings and current maturities of Long-term Borrowings) / (Long-term Borrowings + Short-term Borrowings + current maturities of Long-term Borrowings).
  - (v) Details of due dates of payment of interest and repayment of principal:

| Particulars   | Rated Unsecured Listed Redeemable Non-Convertible Debentures Series 1 | Rated Unsecured Listed Redeemable Non-Convertible Debentures Series 2 |
|---|---|---|
| Previous due date for payment of Interest (has been paid on due date) | December 22, 2017   | December 26, 2017   |
| Next due date for payment of Interest                                 | Not Applicable  | December 24, 2018   |
| Amount of Interest (₹ in Lakhs)                                       | Not Applicable  | 3,970   |
| Repayment of principal (has been paid on due date)                    | December 22, 2017   | Not Applicable  |
| Due Date for the Repayment of Principal                               | Not Applicable  | March 22, 2019  |
| Redemption Amount (₹ in Lakhs)  | Not Applicable  | 50,000  |

- (vi) The Company has 4,000,000 10% redeemable non-cumulative preference shares of ₹ 100 each outstanding as on March 31, 2018 amounting to ₹ 4,000 Lakhs, which are held by the Holding Company, Sun Pharmaceutical Industries Limited (SPIL).
- (vii) Net worth of the Company as on March 31, 2018 is ₹ 110,344 Lakhs excluding Capital Reserve of ₹ 1,856,543 Lakhs.
- 6 The Company has only one reportable segment namely 'Pharmaceuticals'.
- 7 Post implementation of Goods and Service Tax ("GST") with effect from July 1, 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in GST. Revenue from operations for the year ended March 31, 2018 includes excise duty for the three months ended June 30, 2017. Accordingly, revenue from operations for the half year and year ended March 31, 2018 are not comparable with those of the previous periods presented.
- 8 In Compliance with IND AS 20 on Government Grants, the amount of budgetary support under Goods and Service Tax, GST Refunds, to be received from the Government of India in relation to the existing eligible units under the different Industrial Promotion Scheme have been recognised as "Other Operating Income". In past periods these credits were netted off from the excise cost reported in the Statement of Profit and Loss.
- 9 The figures for the half year ended March 31, 2018 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures for the half year ended September 30, 2017. The figures for the half year ended March 31, 2017 are the balancing figures between the audited figures in the respect of the full financial year and the unaudited figures for the half year ended September 30, 2016.
- 10 Figures for the previous year / periods are re-arranged / re-grouped where ever necessary.

**SIGNED FOR IDENTIFICATION BY**  
  
**S R B C & CO LLP**  
**MUMBAI**



For and on behalf of the Board

  
**KALYANASUNDARAM SUBRAMANIAN**  
 Whole time Director & CEO

Mumbai, May 24, 2018

Independent Auditor's Report On Standalone Financial Results Pursuant to the Regulation 52  
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To  
The Board of Directors  
Sun Pharma Laboratories Limited

1. We have audited the accompanying statement of standalone financial results of Sun Pharma Laboratories Limited ('the Company') for the year ended March 31, 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular No. CIR/IMD/DF1/69/2016 dated August 10, 2016 ('the Circular'). This Statement has been prepared on the basis of the audited standalone financial statements for year ended March 31, 2018, which is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to express an opinion on the Statement based on our audit of the standalone financial statements as at and for the year ended March 31, 2018, prepared in accordance with Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of the Regulation and the Circular.
2. We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India. Those standards requires that we plan and perform the audit to obtain reasonable assurance as to whether the Statement is free of material misstatement.
3. An audit involves performing procedures to obtain sufficient audit evidences about the amounts and disclosures in the Statement. The procedures selected depend on the auditor's judgement including the assessment of material misstatement of the Statement, whether due to fraud or error. In making those risk assessment, the auditor considers internal controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - i. is presented in accordance with the requirements of the Regulation, read with the Circular; and
  - ii. gives a true and fair view of the net profit including other comprehensive income and other financial information of the Company for the year ended March 31, 2018
5. The comparative Ind AS financial information of the Company for the half year and year ended March 31, 2017, included in these standalone Ind AS financial results, have been audited by the predecessor auditor. The report of the predecessor auditor on the comparative financial information dated May 25, 2017 expressed an unmodified opinion.



# SRBC & CO LLP

Chartered Accountants

Sun Pharma Laboratories Limited

Page 2 of 2

6. Further, we report that the figures for the half year ended March 31, 2018 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2018 and the published figures for the half year ended September 30, 2017, which were subjected to a limited review, as required under the Regulation and the Circular.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Ravi Bansal  
Partner

Membership No.: 49365



Place: Mumbai

Date: May 24, 2018

**Sun Pharma Laboratories Limited**

Regd. Office : Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
www.spill.co  
CIN : U25200MH1997PLC240268



**May 24, 2018**

**General Manager**  
**BSE Limited,**  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001  
**Scrip Codes: 953164**  
**ISIN Nos: INE915T08024**

**DECLARATION**

We hereby confirm and declare that the Statutory Auditors of the Company i.e. M/s. SRBC & Co LLP, Chartered Accountants have issued the Audit Report on Standalone Financial Results of the Company for the Half year and year ended March 31, 2018 with unmodified opinion.

**For Sun Pharma Laboratories Limited**

**C. S. Muralidharan**  
**Chief Financial Officer**

Date: May 24, 2018  
Place: Mumbai



ATSL/CO/2018-19/ 112-1  
May 24, 2018

To,  
**Sun Pharma Laboratories Limited**  
Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon  
(East), Mumbai 400063

**Kind Attn: Ms. Rachana Kokal**

**Sub: Sun Pharma Laboratories Limited (the "Company") - Letter of Debenture Trustee pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) 2015**

Dear Madam,

We write in our capacity as the Debenture Trustee for the Non-Convertible Debentures (NCDs) aggregating to Rs. 1,000 Crores issued by the Company and listed on the BSE Limited ("Listed Debt Securities").

Pursuant to Regulation 52(4) read with Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) 2015, the Company is required to submit its half yearly/annual financial results to the Stock Exchange, with a letter of the Debenture Trustee (Axis Trustee Services Limited) that the Debenture Trustee has noted the contents furnished by the Company in terms of Regulation 52(4).

In pursuance thereof we hereby confirm that we have received the said information vide your letter dated May 24, 2018 (attached herewith) for the year ended March 31<sup>st</sup>, 2018 along with the relevant/necessary supporting and we have noted the contents in respect of the Listed Debt Securities issued by the Company.

Further please note that we have not independently verified the contents submitted vide your above letter and the aforesaid noting is subject to the following:

1. The Debenture Trustee is relying on the information/status as submitted by the company for the purpose of submission to the Stock Exchange; without reconfirming.
2. Any commitment pertaining to the interest /principal payable on the future due dates are sole commitment on the company's part and Trustee is not liable in any manner if company fails to fulfill / does not fulfill its commitments.

Thanking You,

Yours Faithfully  
For **Axis Trustee Services Limited**

**Makarand Kulkarni**  
Deputy General Manager



**AXIS TRUSTEE SERVICES LTD.**

(A wholly owned subsidiary of Axis Bank)

Corporate Identity Number (CIN): U74999MH2008PLC182264

CORPORATE & REGISTERED OFFICE : Axis House, Bombay Dyeing Mills Compound, Pandurang Budhkar Marg, Worli, Mumbai - 400 025.

TEL : 022-6226 0054 / 6226 0050 Website: www.axistrustee.com